Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections

Asaba et al., Journal of Inflammation Research, doi:10.2147/jir.s474707
Jul 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 419 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 109 treatments. c19hcq.org
Review suggesting that the SARS-CoV-2 spike protein interacts with TLR4 to induce hyperinflammation and severe COVID-19. The spike protein binds TLR4 with high affinity, triggering inflammatory signaling cascades. SARS-CoV-2 infection may also indirectly upregulate TLR4 expression through decreased surfactant production in type II pneumocytes, activation of platelets, and dysregulation of the renin-angiotensin system. Authors suggest that targeting the TLR4 pathway with antagonists like hydroxychloroquine or artesunate, monoclonal antibodies, or aptamers could help alleviate the cytokine storm and severe complications in COVID-19 patients.
Reviews covering hydroxychloroquine for COVID-19 include1-26.
Asaba et al., 31 Jul 2024, peer-reviewed, 6 authors. Contact: terencendonyi.bukong@inrs.ca.
This PaperHCQAll
Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections
Clinton Njinju Asaba, Cyril Jabea Ekabe, Humblenoble Stembridge Ayuk, Bella Nyemkuna Gwanyama, Razieh Bitazar, Terence Ndonyi Bukong
Journal of Inflammation Research, doi:10.2147/jir.s474707
The late 2019 emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, caused profound and unprecedented disruption to the global socio-economic structure, negatively affecting millions of lives worldwide. A typical hallmark of severe COVID-19 is hyper inflammation due to aberrant cytokine release (cytokine storm) by innate immune cells. Recent studies have revealed that SARS-CoV-2, through its spike (S) protein, can activate the body's innate immune cells via Toll-Like Receptors (TLRs), particularly TLR4. In silico studies have demonstrated that the S protein binds with high affinity to TLR4, triggering downstream signaling processes that result in pro-inflammatory cytokine release. Compared to other TLRs, such as TLR2, TLR4 plays a more significant role in initiating and sustaining the inflammatory response associated with severe COVID-19. Furthermore, interactions between the virus and target cells can enhance the cellular expression of TLR4, making cells more susceptible to viral interactions and subsequent inflammation. This increased expression of TLR4 upon viral entry creates a feedback loop, where heightened TLR4 levels lead to amplified inflammatory responses, contributing to the severity of the disease. Additionally, TLR4's potent activation of inflammatory pathways sets it apart from other TLRs, underscoring its pivotal role in the pathogenesis of COVID-19. In this review, we thoroughly explore the multitude of regulatory signaling pathways that SARS-CoV-2 employs to incite inflammation. We specifically focus on the critical impact of TLR4 activation compared to other TLRs, highlighting how TLR4's interactions with the viral S protein can exacerbate the severity of COVID-19. By delving into the mechanisms of TLR4mediated inflammation, we aim to shed light on potential therapeutic targets that could mitigate the inflammatory damage caused by severe COVID-19. Understanding the unique role of TLR4 in the context of SARS-CoV-2 infection could pave the way for novel treatment strategies that specifically inhibit this receptor's activity, thereby reducing the overall disease burden and improving patient outcomes.
Abbreviations ACE2, Angiotensin-converting enzyme 2; AP-1, activator protein-1; ARDS, acute respiratory distress syndrome; ATI, alveolar type I pneumocytes; ATII, alveolar type II pneumocytes; AT1-R, Angiotensin II Type 1 Receptor; AT2-R, Angiotensin II Type 2 Receptor; DAMPs, danger associated molecular patterns; FAK, focal adhesion kinase; IRF3, interferon regulatory factor-3; LBP, LPS binding protein; MD2, myeloid differentiation factor 2; MyD88, myeloid differentiation primary response 88; NADPH, nicotinamide adenine dinucleotide phosphate; NF-kB, Nuclear factor-kB; NSAIDs, Non-steroidal anti-inflammatory drugs; PAMPs, pathogen associated molecular patterns; PLC, phospholipase C; PSGL-1, P-selectin glycoprotein ligand 1; RAS, renin-angiotensin system; RBD, receptor-binding domain; sGP, secreted glycoprotein; TF, tissue factor; TIR, toll-IL1 receptor; TLR, Toll-like receptor; TMPRSS2, transmembrane serine protease 2; TRIF, toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-β. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. ..
References
Aboudounya, Heads, Dozio, Bind and Activate TLR4 to Increase ACE2 expression, facilitating entry and causing hyperinflammation, Mediators Inflamm, doi:10.1155/2021/8874339
Adamzik, Frey, Sixt, ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS, Eur Respir J, doi:10.1183/09031936.00046106
Akbar, Gilroy, Aging immunity may exacerbate COVID-19, Science, doi:10.1126/science.abb0762
Akira, Takeda, Toll-like receptor signalling, Nat Rev Immunol, doi:10.1038/nri1391
Asakura, Ogawa, COVID-19-associated coagulopathy and disseminated intravascular coagulation, Int J Hematol, doi:10.1007/s12185-020-03029-y
Batah, Fabro, Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians, Respir Med, doi:10.1016/j.rmed.2020.106239
Bhattacharya, Sharma, Mallick, Sharma, Lee et al., Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex, Infect Genet Evol, doi:10.1016/j.meegid.2020.104587
Calabrese, Annunziata, Coppola, ACE Gene I/D Polymorphism and Acute Pulmonary Embolism in COVID19 Pneumonia: A potential predisposing role, Front Med Lausanne, doi:10.3389/fmed.2020.631148
Carcaterra, Caruso, Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: a physio-pathological theory, Med Hypotheses, doi:10.1016/j.mehy.2020.110412
Carnevale, Cammisotto, Bartimoccia, Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection, Circ Res, doi:10.1161/circresaha.122.321541
Chen, Lan, Ye, Cytokine Storm: The primary determinant for the pathophysiological evolution of coVID-19 Deterioration, Front Immunol, doi:10.3389/fimmu.2021.589095
Chen, Li, Liu, Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection, Cell Rep Phys Sci, doi:10.1016/j.xcrp.2023.101249
Choudhury, Das, Patra, Mukherjee, In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans, J Med Virol, doi:10.1002/jmv.26776
Choudhury, Gupta, Panda, Rana, Mukherjee, Designing AbhiSCoVac -A single potential vaccine for all 'Corona culprits': immunoinformatics and immune simulation approaches, J Mol Liq, doi:10.1016/j.molliq.2022.118633
Choudhury, Mukherjee, In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs, J Med Virol, doi:10.1002/jmv.25987
Dai, Wang, Wang, Toll-like receptor signaling in severe acute respiratory syndrome Coronavirus 2-Induced innate immune responses and the potential application value of toll-like receptor immunomodulators in patients with coronavirus disease 2019, Front Microbiol, doi:10.3389/fmicb.2022.948770
El-Arif, Farhat, Khazaal, The Renin-Angiotensin System: A key role in SARS-CoV-2-Induced COVID-19, Molecules, doi:10.3390/molecules26226945
El-Arif, Khazaal, Farhat, Angiotensin II Type I Receptor (AT1R): the Gate towards COVID-19-Associated Diseases, Molecules, doi:10.3390/molecules27072048
Etter, Martins, Kulsvehagen, Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study, Nat Commun, doi:10.1038/s41467-022-34068-0
Ferreira, Soares, De Azevedo-Quintanilha, SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes, Cell Death Discov, doi:10.1038/s41420-021-00428-w
Fontes-Dantas, Fernandes, Gutman, SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice, Cell Rep, doi:10.1155/2021/8874339
Ghafouri-Fard, Noroozi, Omrani, Angiotensin converting enzyme: a review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection, Vascul Pharmacol, doi:10.1016/j.vph.2020.106680
Grandvaux, Servant, Tenoever, Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes, J Virol, doi:10.1128/jvi.76.11.5532-5539.2002
Gupta, Madhavan, Sehgal, Extrapulmonary manifestations of COVID-19, Nat Med, doi:10.1038/s41591-020-0968-3
Han, Mallampalli, The Role of surfactant in lung disease and host defense against pulmonary infections, Ann Am Thorac Soc, doi:10.1513/AnnalsATS.201411-507FR
Hm, Gareeb, Mostafa-Hedeab, Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19, Front Immunol, doi:10.3389/fimmu.2021.749291
Jurk, Kehrel, Platelets: physiology and biochemistry, Semin Thromb Hemost, doi:10.1055/s-2005-916671
Karnik, Unal, Kemp, International Union of Basic and Clinical Pharmacology, XCIX Angiot Recep, doi:10.1124/pr.114.010454
Kaushik, Bhandari, Kuhad, TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2, Expert Opin Ther Targets, doi:10.1080/14728222.2021.1918103
Kawasaki, Kawai, Toll-like receptor signaling pathways, Front Immunol, doi:10.3389/fimmu.2014.00461
Khan, Khan, Jalal, Ul-Haq, Uddin, Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant, Virology, doi:10.1016/j.virol.2022.05.001
Kombe, Biteghe, Ndoutoume, CD8(+) T-cell immune escape by SARS-CoV-2 variants of concern, Front Immunol, doi:10.3389/fimmu.2022.962079
Lambert, Yang, Liu, Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A, PLoS One, doi:10.1371/journal.pone.0051618
Lukassen, Chua, Trefzer, SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells, EMBO j, doi:10.15252/embj.20105114
Mahmoudi, Alavizadeh, Hosseini, Harnessing aptamers against COVID-19: a therapeutic strategy, Drug Discov Today, doi:10.1016/j.drudis.2023.103663
Mousavizadeh, Ghasemi, Genotype and phenotype of COVID-19: Their roles in pathogenesis, J Microbiol Imml Infect, doi:10.1016/j.jmii.2020.03.022
Mukherjee, Toll-like receptor 4 in COVID-19: friend or foe?, Future Virol, doi:10.2217/fvl-2021-0249
Ochs, Nyengaard, Jung, The number of alveoli in the human lung, Am J Respir Crit Care Med, doi:10.1164/rccm.200308-1107OC
Okamoto, Ichikawa, The pivotal role of the angiotensin-II-NF-κB axis in the development of COVID-19 pathophysiology, Hypertens Res, doi:10.1038/s41440-020-00560-7
Olejnik, Hume, Mühlberger, Dutch, Toll-like receptor 4 in acute viral infection: too much of a good thing, PLoS Pathog, doi:10.1371/journal.ppat.1007390
Rallabhandi, Phillips, Boukhvalova, Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2, mBio, doi:10.1128/mBio.00218-12
Rauch, Bonderman, Bohrmann, Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor, Blood, doi:10.1182/blood.V96.1.170
Rysz, Al-Saadi, Sjöström, COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system, Journal of Inflammation Research, doi:10.1038/s41467-021-22713-z
Schabbauer, Luyendyk, Crozat, TLR4/CD14-mediated PI3K activation is an essential component of interferon-dependent VSV resistance in macrophages, Mol Immunol, doi:10.1016/j.molimm.2008.02.001
Scherm, Gangloff, Gay, Activation of Toll-like receptor 4 by Ebola virus-shed glycoprotein is direct and requires the internal fusion loop but not glycosylation, Cell Rep, doi:10.1016/j.celrep.2022.111562
Shirato, Kizaki, SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages, Heliyon, doi:10.1016/j.heliyon.2021.e06187
Si, Ma, Wang, Efficacy and safety of Jinhua Qinggan granules in the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Medicine, doi:10.1097/md.0000000000033545
Siddiqui, Desai, Amirkhosravi, Amaya, Francis, The presence and release of tissue factor from human platelets, Platelets, doi:10.1080/09537100220146398
Simon, Veit, Osterrieder, Gradzielski, Surfactants -Compounds for inactivation of SARS-CoV-2 and other enveloped viruses, Curr Opin Colloid Interface Sci, doi:10.1016/j.cocis.2021.101479
Takano, Pulmonary surfactant itself must be a strong defender against SARS-CoV-2, Med Hypotheses, doi:10.1016/j.mehy.2020.110020
Tang, Liang, Wang, Qinhuo Shanggan oral solution resolves acute lung injury by down-regulating TLR4/NF-κB signaling cascade and inhibiting NLRP3 inflammasome activation, Front Immunol, doi:10.3389/fimmu.2023.1285550
Tondini, Reintjens, Castello, Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control, doi:10.1038/s41541-022-00484-y
Tsai, Lin, Huang, The role of calpain-myosin 9-Rab7b pathway in mediating the expression of Toll-like receptor 4 in platelets: a novel mechanism involved in α-granules trafficking, PLoS One, doi:10.1371/journal.pone.0085833
V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat Rev Microbiol, doi:10.1038/s41579-020-00468-6
Van Der Made, Simons, Schuurs-Hoeijmakers, Presence of genetic variants among young men with severe COVID-19, JAMA, doi:10.1001/jama.2020.13719
Voelker, Numata, Phospholipid regulation of innate immunity and respiratory viral infection, J Biol Chem, doi:10.1074/jbc.AW118.003229
Watson, Madsen, Clark, SP-A and SP-D: dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties, Front Immunol, doi:10.3389/fimmu.2020.622598
Yang, Wang, Huang, Myeloid Angiotensin II Type 1 Receptor Mediates Macrophage Polarization and Promotes Vascular Injury in DOCA/Salt Hypertensive Mice, Front Pharmacol, doi:10.3389/fphar.2022.879693
Yang, Zhang, Wang, Aptamer blocking S-TLR4 interaction selectively inhibits SARS-CoV-2 induced inflammation, Signal Transduct Target Ther, doi:10.1038/s41392-022-00968-2
Zhang, Liu, Wang, SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19, J Hematol Oncol, doi:10.1186/s13045-020-00954-7
Zhang, Wang, Wang, Qingwenzhike Prescription Alleviates Acute Lung Injury Induced by LPS via Inhibiting TLR4/NF-kB Pathway and NLRP3 Inflammasome Activation, Front Pharmacol, doi:10.3389/fphar.2021.790072
Zhao, Kuang, Li, Publisher Correction: SARS-CoV-2 spike protein interacts with and activates TLR4, Cell Res, doi:10.1038/s41422-021-00501-0
Zhao, Li, Li, Xu, Xu, The mechanism of multiple organ dysfunction syndrome in patients with COVID-19, J Med Virol, doi:10.1002/jmv.27627
Zhao, Qin, Liu, Orally administered BZL-sRNA-20 oligonucleotide targeting TLR4 effectively ameliorates acute lung injury in mice, Sci China Life Sci, doi:10.1007/s11427-022-2219-0
Zhou, Ren, Zhang, Heightened innate immune responses in the respiratory tract of COVID-19 Patients, Cell Host Microbe, doi:10.1016/j.chom.2020.04.017
Zhou, Wang, Zhang, Effect of TLR4/MyD88 signaling pathway on sepsis-associated acute respiratory distress syndrome in rats, via regulation of macrophage activation and inflammatory response, Exp Ther Med, doi:10.3892/etm.2018.5815
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet, doi:10.1016/s0140-6736(20)30566-3
Zhu, Han, Wang, Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/ MyD88/NF-κB pathway, J Ethnopharmacol, doi:10.1016/j.jep.2022.115763
Íñiguez, Pérez-Matute, Villoslada-Blanco, ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study, Front Endocrinol, doi:10.3389/fendo.2021.688071
{ 'indexed': {'date-parts': [[2024, 7, 27]], 'date-time': '2024-07-27T00:22:50Z', 'timestamp': 1722039770823}, 'reference-count': 69, 'publisher': 'Informa UK Limited', 'license': [ { 'start': { 'date-parts': [[2024, 7, 1]], 'date-time': '2024-07-01T00:00:00Z', 'timestamp': 1719792000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/3.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.2147/jir.s474707', 'type': 'journal-article', 'created': {'date-parts': [[2024, 7, 26]], 'date-time': '2024-07-26T04:10:14Z', 'timestamp': 1721967014000}, 'page': '5077-5091', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity ' 'in COVID-19 Infections', 'prefix': '10.2147', 'volume': 'Volume 17', 'author': [ {'given': 'Clinton Njinju', 'family': 'Asaba', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6910-3719', 'authenticated-orcid': True, 'given': 'Cyril', 'family': 'Ekabe', 'sequence': 'additional', 'affiliation': []}, {'given': 'Humblenoble', 'family': 'Ayuk', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0009-0007-6931-7929', 'authenticated-orcid': True, 'given': 'Bella', 'family': 'Gwanyama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Razieh', 'family': 'Bitazar', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3898-0617', 'authenticated-orcid': True, 'given': 'Terence', 'family': 'Bukong', 'sequence': 'additional', 'affiliation': []}], 'member': '301', 'published-online': {'date-parts': [[2024, 7]]}, 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'DOI': '10.1016/s0140-6736(20)30566-3', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'first-page': '103663', 'DOI': '10.1016/j.drudis.2023.103663', 'volume': '28', 'author': 'Mahmoudi', 'year': '2023', 'journal-title': 'Drug Discov Today'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'first-page': '106239', 'DOI': '10.1016/j.rmed.2020.106239', 'volume': '176', 'author': 'Batah', 'year': '2021', 'journal-title': 'Respir Med'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'first-page': '155', 'DOI': '10.1038/s41579-020-00468-6', 'volume': '19', 'author': 'V’Kovski', 'year': '2021', 'journal-title': 'Nat Rev Microbiol'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'first-page': '962079', 'DOI': '10.3389/fimmu.2022.962079', 'volume': '13', 'author': 'Kombe Kombe', 'year': '2022', 'journal-title': 'Front Immunol'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': '883', 'DOI': '10.1016/j.chom.2020.04.017', 'volume': '27', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Cell Host Microbe'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'first-page': '1886', 'DOI': '10.1002/jmv.27627', 'volume': '94', 'author': 'Zhao', 'year': '2022', 'journal-title': 'J Med Virol'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'first-page': '43', 'DOI': '10.1038/s41420-021-00428-w', 'volume': '7', 'author': 'Ferreira', 'year': '2021', 'journal-title': 'Cell Death Discov'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'first-page': '461', 'DOI': '10.3389/fimmu.2014.00461', 'volume': '5', 'author': 'Kawasaki', 'year': '2014', 'journal-title': 'Front Immunol'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'first-page': '2476', 'DOI': '10.1002/jmv.26776', 'volume': '93', 'author': 'Choudhury', 'year': '2021', 'journal-title': 'J Med Virol'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'first-page': '104587', 'DOI': '10.1016/j.meegid.2020.104587', 'volume': '85', 'author': 'Bhattacharya', 'year': '2020', 'journal-title': 'Infect Genet Evol'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'first-page': '2105', 'DOI': '10.1002/jmv.25987', 'volume': '92', 'author': 'Choudhury', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'first-page': '4282', 'DOI': '10.1074/jbc.AW118.003229', 'volume': '294', 'author': 'Voelker', 'year': '2019', 'journal-title': 'J Biol Chem'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'first-page': '948770', 'DOI': '10.3389/fmicb.2022.948770', 'volume': '13', 'author': 'Dai', 'year': '2022', 'journal-title': 'Front Microbiol'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'first-page': 'e1007390', 'DOI': '10.1371/journal.ppat.1007390', 'volume': '14', 'author': 'Olejnik', 'year': '2018', 'journal-title': 'PLoS Pathog'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/mBio.00218-12', 'volume': '3', 'author': 'Rallabhandi', 'year': '2012', 'journal-title': 'mBio'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '2790', 'DOI': '10.1016/j.molimm.2008.02.001', 'volume': '45', 'author': 'Schabbauer', 'year': '2008', 'journal-title': 'Mol Immunol'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'first-page': '111562', 'DOI': '10.1016/j.celrep.2022.111562', 'volume': '41', 'author': 'Scherm', 'year': '2022', 'journal-title': 'Cell Rep'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'first-page': '8874339', 'DOI': '10.1155/2021/8874339', 'volume': '2021', 'author': 'Aboudounya', 'year': '2021', 'journal-title': 'Mediators Inflamm'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'first-page': 'e06187', 'DOI': '10.1016/j.heliyon.2021.e06187', 'volume': '7', 'author': 'Shirato', 'year': '2021', 'journal-title': 'Heliyon'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'first-page': '112189', 'DOI': '10.1155/2021/8874339', 'volume': '42', 'author': 'Fontes-Dantas', 'year': '2023', 'journal-title': 'Cell Rep'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'first-page': '6777', 'DOI': '10.1038/s41467-022-34068-0', 'volume': '13', 'author': 'Etter', 'year': '2022', 'journal-title': 'Nat Commun'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'first-page': '28', 'DOI': '10.1016/j.virol.2022.05.001', 'volume': '572', 'author': 'Khan', 'year': '2022', 'journal-title': 'Virology'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'first-page': '589095', 'DOI': '10.3389/fimmu.2021.589095', 'volume': '12', 'author': 'Chen', 'year': '2021', 'journal-title': 'Front Immunol'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'first-page': '120', 'DOI': '10.1164/rccm.200308-1107OC', 'volume': '169', 'author': 'Ochs', 'year': '2004', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': 'ref26', 'doi-asserted-by': 'publisher', 'first-page': '765', 'DOI': '10.1513/AnnalsATS.201411-507FR', 'volume': '12', 'author': 'Han', 'year': '2015', 'journal-title': 'Ann Am Thorac Soc'}, { 'key': 'ref27', 'doi-asserted-by': 'publisher', 'first-page': '110412', 'DOI': '10.1016/j.mehy.2020.110412', 'volume': '146', 'author': 'Carcaterra', 'year': '2021', 'journal-title': 'Med Hypotheses'}, { 'key': 'ref28', 'doi-asserted-by': 'publisher', 'first-page': 'e105114', 'DOI': '10.15252/embj.20105114', 'volume': '39', 'author': 'Lukassen', 'year': '2020', 'journal-title': 'EMBO j'}, { 'key': 'ref29', 'doi-asserted-by': 'publisher', 'first-page': '622598', 'DOI': '10.3389/fimmu.2020.622598', 'volume': '11', 'author': 'Watson', 'year': '2020', 'journal-title': 'Front Immunol'}, { 'key': 'ref30', 'doi-asserted-by': 'publisher', 'first-page': '101479', 'DOI': '10.1016/j.cocis.2021.101479', 'volume': '55', 'author': 'Simon', 'year': '2021', 'journal-title': 'Curr Opin Colloid Interface Sci'}, { 'key': 'ref31', 'doi-asserted-by': 'publisher', 'first-page': '110020', 'DOI': '10.1016/j.mehy.2020.110020', 'volume': '144', 'author': 'Takano', 'year': '2020', 'journal-title': 'Med Hypotheses'}, { 'key': 'ref32', 'doi-asserted-by': 'publisher', 'first-page': '499', 'DOI': '10.1038/nri1391', 'volume': '4', 'author': 'Akira', 'year': '2004', 'journal-title': 'Nat Rev Immunol'}, { 'key': 'ref33', 'doi-asserted-by': 'publisher', 'first-page': '5532', 'DOI': '10.1128/jvi.76.11.5532-5539.2002', 'volume': '76', 'author': 'Grandvaux', 'year': '2002', 'journal-title': 'J Virol'}, { 'key': 'ref34', 'doi-asserted-by': 'publisher', 'first-page': '825', 'DOI': '10.1038/s41422-021-00501-0', 'volume': '31', 'author': 'Zhao', 'year': '2021', 'journal-title': 'Cell Res'}, { 'key': 'ref35', 'doi-asserted-by': 'publisher', 'first-page': '381', 'DOI': '10.1055/s-2005-916671', 'volume': '31', 'author': 'Jurk', 'year': '2005', 'journal-title': 'Semin Thromb Hemost'}, { 'key': 'ref36', 'doi-asserted-by': 'publisher', 'first-page': '120', 'DOI': '10.1186/s13045-020-00954-7', 'volume': '13', 'author': 'Zhang', 'year': '2020', 'journal-title': 'J Hematol Oncol'}, { 'key': 'ref37', 'doi-asserted-by': 'publisher', 'first-page': '45', 'DOI': '10.1007/s12185-020-03029-y', 'volume': '113', 'author': 'Asakura', 'year': '2021', 'journal-title': 'Int J Hematol'}, { 'key': 'ref38', 'doi-asserted-by': 'publisher', 'first-page': '170', 'DOI': '10.1182/blood.V96.1.170', 'volume': '96', 'author': 'Rauch', 'year': '2000', 'journal-title': 'Blood'}, { 'key': 'ref39', 'doi-asserted-by': 'publisher', 'first-page': '247', 'DOI': '10.1080/09537100220146398', 'volume': '13', 'author': 'Siddiqui', 'year': '2002', 'journal-title': 'Platelets'}, { 'key': 'ref40', 'doi-asserted-by': 'publisher', 'first-page': 'e85833', 'DOI': '10.1371/journal.pone.0085833', 'volume': '9', 'author': 'Tsai', 'year': '2014', 'journal-title': 'PLoS One'}, { 'key': 'ref41', 'doi-asserted-by': 'publisher', 'first-page': '290', 'DOI': '10.1161/circresaha.122.321541', 'volume': '132', 'author': 'Carnevale', 'year': '2023', 'journal-title': 'Circ Res'}, { 'key': 'ref42', 'doi-asserted-by': 'publisher', 'first-page': '2417', 'DOI': '10.1038/s41467-021-22713-z', 'volume': '12', 'author': 'Rysz', 'year': '2021', 'journal-title': 'Nat Commun'}, { 'key': 'ref43', 'doi-asserted-by': 'publisher', 'first-page': '754', 'DOI': '10.1124/pr.114.010454', 'volume': '67', 'author': 'Karnik', 'year': '2015', 'journal-title': 'XCIX Angiot Recep'}, { 'key': 'ref44', 'doi-asserted-by': 'publisher', 'first-page': '6945', 'DOI': '10.3390/molecules26226945', 'volume': '26', 'author': 'El-Arif', 'year': '2021', 'journal-title': 'Molecules'}, { 'key': 'ref45', 'doi-asserted-by': 'publisher', 'first-page': '106680', 'DOI': '10.1016/j.vph.2020.106680', 'volume': '130', 'author': 'Ghafouri-Fard', 'year': '2020', 'journal-title': 'Vascul Pharmacol'}, { 'key': 'ref46', 'doi-asserted-by': 'publisher', 'first-page': '159', 'DOI': '10.1016/j.jmii.2020.03.022', 'volume': '54', 'author': 'Mousavizadeh', 'year': '2021', 'journal-title': 'J Microbiol Imml Infect'}, { 'key': 'ref47', 'doi-asserted-by': 'publisher', 'first-page': '482', 'DOI': '10.1183/09031936.00046106', 'volume': '29', 'author': 'Adamzik', 'year': '2007', 'journal-title': 'Eur Respir J'}, { 'key': 'ref48', 'doi-asserted-by': 'publisher', 'first-page': '631148', 'DOI': '10.3389/fmed.2020.631148', 'volume': '7', 'author': 'Calabrese', 'year': '2020', 'journal-title': 'Front Med Lausanne'}, { 'key': 'ref49', 'doi-asserted-by': 'publisher', 'first-page': '688071', 'DOI': '10.3389/fendo.2021.688071', 'volume': '12', 'author': 'Íñiguez', 'year': '2021', 'journal-title': 'Front Endocrinol'}, { 'key': 'ref50', 'doi-asserted-by': 'publisher', 'first-page': '749291', 'DOI': '10.3389/fimmu.2021.749291', 'volume': '12', 'author': 'Al-Kuraishy', 'year': '2021', 'journal-title': 'Front Immunol'}, { 'key': 'ref51', 'doi-asserted-by': 'publisher', 'first-page': '2048', 'DOI': '10.3390/molecules27072048', 'volume': '27', 'author': 'El-Arif', 'year': '2022', 'journal-title': 'Molecules'}, { 'key': 'ref52', 'doi-asserted-by': 'publisher', 'first-page': '126', 'DOI': '10.1038/s41440-020-00560-7', 'volume': '44', 'author': 'Okamoto', 'year': '2021', 'journal-title': 'Hypertens Res'}, { 'key': 'ref53', 'doi-asserted-by': 'publisher', 'first-page': '879693', 'DOI': '10.3389/fphar.2022.879693', 'volume': '13', 'author': 'Yang', 'year': '2022', 'journal-title': 'Front Pharmacol'}, { 'key': 'ref54', 'doi-asserted-by': 'publisher', 'first-page': '415', 'DOI': '10.2217/fvl-2021-0249', 'volume': '17', 'author': 'Mukherjee', 'year': '2022', 'journal-title': 'Future Virol'}, { 'key': 'ref55', 'doi-asserted-by': 'publisher', 'first-page': '118633', 'DOI': '10.1016/j.molliq.2022.118633', 'volume': '351', 'author': 'Choudhury', 'year': '2022', 'journal-title': 'J Mol Liq'}, { 'key': 'ref56', 'doi-asserted-by': 'publisher', 'first-page': '3376', 'DOI': '10.3892/etm.2018.5815', 'volume': '15', 'author': 'Zhou', 'year': '2018', 'journal-title': 'Exp Ther Med'}, { 'key': 'ref57', 'doi-asserted-by': 'publisher', 'first-page': '491', 'DOI': '10.1080/14728222.2021.1918103', 'volume': '25', 'author': 'Kaushik', 'year': '2021', 'journal-title': 'Expert Opin Ther Targets'}, { 'key': 'ref58', 'doi-asserted-by': 'publisher', 'first-page': '790072', 'DOI': '10.3389/fphar.2021.790072', 'volume': '12', 'author': 'Zhang', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'key': 'ref59', 'doi-asserted-by': 'publisher', 'first-page': '1589', 'DOI': '10.1007/s11427-022-2219-0', 'volume': '66', 'author': 'Zhao', 'year': '2023', 'journal-title': 'Sci China Life Sci'}, { 'key': 'ref60', 'doi-asserted-by': 'publisher', 'first-page': '1285550', 'DOI': '10.3389/fimmu.2023.1285550', 'volume': '14', 'author': 'Tang', 'year': '2023', 'journal-title': 'Front Immunol'}, { 'key': 'ref61', 'doi-asserted-by': 'publisher', 'first-page': '120', 'DOI': '10.1038/s41392-022-00968-2', 'volume': '7', 'author': 'Yang', 'year': '2022', 'journal-title': 'Signal Transduct Target Ther'}, { 'key': 'ref62', 'doi-asserted-by': 'publisher', 'first-page': '115763', 'DOI': '10.1016/j.jep.2022.115763', 'volume': '301', 'author': 'Zhu', 'year': '2023', 'journal-title': 'J Ethnopharmacol'}, { 'key': 'ref63', 'doi-asserted-by': 'publisher', 'first-page': '1017', 'DOI': '10.1038/s41591-020-0968-3', 'volume': '26', 'author': 'Gupta', 'year': '2020', 'journal-title': 'Nat Med'}, { 'key': 'ref64', 'doi-asserted-by': 'publisher', 'first-page': '256', 'DOI': '10.1126/science.abb0762', 'volume': '369', 'author': 'Akbar', 'year': '2020', 'journal-title': 'Science'}, { 'key': 'ref65', 'doi-asserted-by': 'publisher', 'first-page': '663', 'DOI': '10.1001/jama.2020.13719', 'volume': '324', 'author': 'van der Made', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': 'ref66', 'doi-asserted-by': 'publisher', 'first-page': 'e51618', 'DOI': '10.1371/journal.pone.0051618', 'volume': '7', 'author': 'Lambert', 'year': '2012', 'journal-title': 'PLoS One'}, { 'key': 'ref67', 'doi-asserted-by': 'publisher', 'first-page': '101249', 'DOI': '10.1016/j.xcrp.2023.101249', 'volume': '4', 'author': 'Chen', 'year': '2023', 'journal-title': 'Cell Rep Phys Sci'}, { 'key': 'ref68', 'doi-asserted-by': 'publisher', 'first-page': 'e33545', 'DOI': '10.1097/md.0000000000033545', 'volume': '102', 'author': 'Si', 'year': '2023', 'journal-title': 'Medicine'}, { 'key': 'ref69', 'doi-asserted-by': 'publisher', 'first-page': '64', 'DOI': '10.1038/s41541-022-00484-y', 'volume': '7', 'author': 'Tondini', 'year': '2022', 'journal-title': 'NPJ Vaccines'}], 'container-title': 'Journal of Inflammation Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.dovepress.com/article/download/94557', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.dovepress.com/article/download/94557', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 7, 26]], 'date-time': '2024-07-26T04:10:17Z', 'timestamp': 1721967017000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.dovepress.com/interplay-of-tlr4-and-sars-cov-2-unveiling-the-complex-mechanisms-of-i-peer-reviewed-fulltext-article-JIR'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 7]]}, 'references-count': 69, 'URL': 'http://dx.doi.org/10.2147/jir.s474707', 'relation': {}, 'ISSN': ['1178-7031'], 'subject': [], 'container-title-short': 'JIR', 'published': {'date-parts': [[2024, 7]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit